CRO/CMO
Biopharma
-
NUVATION BIO (ANNOUNCED BUSINESS COMBINATION AGREEMENT WITH PANACEA ACQUISITION (NYSE:PANA / SPAC) ON OCT 21, 2020)*
A biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology (*Combination subject to customary closing conditions and completion of the transaction)
-
CEREVEL THERAPEUTICS (TRADING OF COMMON STOCK AND WARRANTS COMMENCED ON U.S. NASDAQ ON OCT 28, 2020 UNDER TICKER SYMBOLS “CERE” AND “CEREW” AFTER COMPLETION OF BUSINESS COMBINATION WITH ARYA SCIENCES ACQUISITION CORP II)
A clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies
Medtech
Life Science Technologies / Tools
-
GRAIL (ANNOUNCED ACQUISITION BY ILLUMINA ON SEP 22, 2020)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products for the early detection of cancer. (*Acquisition subject to customary closing conditions and completion of the transaction)
-
RAPID MICRO BIOSYSTEMS
Based in Boston, Massachusetts, Rapid Micro Biosystems is the first provider of the fully automated, high-volume and secure Microbial Quality Control (MQC) solution for pharmaceutical manufacturing (primary focus), food and beverage safety, personal care manufacturing, environmental water sector, industrial processing and diagnostics.
Digital Health
CRO/CMO
Biopharma
Medtech
Digital Health
-
LINKDOC
LinkDoc Technology Limited is a leading oncology big data company, based in Beijing, China. The company has established partnerships with more than 200 of China's top oncology hospitals for the collection, collation and analysis of cancer patients' medical records and clinical data. To-date the company has built a cloud-based repository of more than 400,000 oncology medical records covering all types of cancers.
Biopharma
-
SORRENTO
Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento’s lead products are multiple late-stage biosimilar and biobetter antibodies as well as clinical CAR-T therapies targeting solid tumors.
-
NUVATION BIO (ANNOUNCED BUSINESS COMBINATION AGREEMENT WITH PANACEA ACQUISITION (NYSE:PANA / SPAC) ON OCT 21, 2020)*
A biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology (*Combination subject to customary closing conditions and completion of the transaction)
-
CEREVEL THERAPEUTICS (TRADING OF COMMON STOCK AND WARRANTS COMMENCED ON U.S. NASDAQ ON OCT 28, 2020 UNDER TICKER SYMBOLS “CERE” AND “CEREW” AFTER COMPLETION OF BUSINESS COMBINATION WITH ARYA SCIENCES ACQUISITION CORP II)
A clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies
Medtech
-
AXONICS MODULATION (IPO ON U.S. NASDAQ ON OCT 31, 2018)
Axonics Modulation (NASDAQ:AXNX) is a medtech company focused on the development, and commercialization of innovative and minimally invasive sacral neuromodulation (“SNM”) solutions. SNM therapy is primarily used to treat patients with overactive bladder (“OAB”), fecal incontinence (“FI”) and urinary retention (“UR”). Axonics currently has marketing approvals in Europe, Canada, and Australia for OAB, FI, and UR.
-
PULMONX (IPO ON U.S. NASDAQ ON OCT 1, 2020)
Pulmonx is a medtech company focused on developing life-changing technologies that improve the lives of patients suffering from COPD. Its innovative product, Zephyr Valve, is the first minimally-invasive device approved by the US FDA for treating patients with severe emphysema.
-
VENCLOSE
Venclose is a Silicon Valley medical technology company developing next-generation solutions for the treatment of venous reflux disease, also known as chronic venous insufficiency (CVI). The VENCLOSE RF Ablation System offers physicians more versatility than earlier generation endovenous radiofrequency ablation technologies.
Life Science Technologies / Tools
-
GRAIL (ANNOUNCED ACQUISITION BY ILLUMINA ON SEP 22, 2020)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products for the early detection of cancer. (*Acquisition subject to customary closing conditions and completion of the transaction)